Abstract
Human chorionic gonadotropin (hCG) is a glycoprotein composed of two dissimilar subunits, α- and β-subunit, held together by charge interactions. hCG is produced by trophoblastic cells of the placenta in both pregnancy and gestational trophoblastic diseases. It is a remarkable glycoprotein in that up to 35% of the molecular weight (MW) is from oligosaccharide side chains. hCG is sometimes considered a mucopolysaccharide, like collagen, because of the large carbohydrate component. There is wide variation in hCG structure throughout normal and abnormal pregnancies, and in gestational trophoblastic diseases. In addition to “regular” hCG (hCG with intact subunits and the midtrimester pregnancy-like complement of oligosaccharides), at least six other key variants are present in serum samples: hyperglycosylated hCG, nicked hCG, hCG missing the β-subunit C-terminal peptide, free β-subunit, hyperglycosylated free β-subunit, and nicked free β-subunit as well as multiple combinations of these variants (i.e., nicked hyperglycosylated hCG missing the β-subunit C-terminal peptide). The same seven molecules plus the β-core fragment can be detected in urine samples (1–9). Table 1 and Fig. 1 summarize the structures of these key hCG-related molecules, which vary in size from β-core fragment (MW 9000–10,000) to hyperglycosylated hCG (MW 38,00042,000). hCG and related molecules may vary widely in charge because of differences in sialic acid content. As shown in Fig. 2, multiple charge isoforms in the range pI 3–7 are found in serum and urine samples, and in the range of pI 3–8 in hyperglycosylated hCG.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Kovalesyskaya G, Birken S, Kakuma T, O’Connor JF. Early pregnancy human chorionic gonodotropin (hCG) isoforms measured by immunometric assay for choriocarcinoma-like hCG. J Endocrinol 1999; 161: 99–106.
Cole LA, Shahabi S, Oz UA, Bahado-Singh RO, Mahoney MJ. Hyperglycosylated hCG (invasive trophoblastic antigen) immunoassay: a new basis for gestational down syndrome screening. Clin Chem 1999; 45: 2109–2119.
Butler SA, Khanlian SA, Cole LA. Detection of early pregnancy forms of hCG by home pregnancy test devices. Clin Chem 2001; 47: 2131–2136.
Cole LA, Shahabi S, Butler SA, et al. Utility of commonly used commercial hCG immunoassays in the diagnosis and management of trophoblastic diseases. Clin Chem, 2001; 47: 308–315.
Cole LA, Kohorn EI, Kim GS. Detecting and monitoring trophoblastic disease: new perspectives in measuring human chorionic gonadotropin levels. J Reprod Med 1994; 39: 193–200.
Kohorn EI, Cole LA. Nicked human chorionic gonadotropin in trophoblastic disease. Intl J Obstet Gynecol 2000; 10: 330–335.
Elliott M, Kardana A, Lustbader JW, Cole LA. Carbohydrate and peptide structure of the a-and (3-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine 1997; 7: 15–32.
Cole LA, Kardana A, Park S-Y, Braunstein GD. The deactivation of hCG by nicking and dissociation. J Clin Endocrinol Metab 1993; 76; 704–713.
Cole LA, Kardana A. Discordant results in human chorionic gonadotropin assays. Clin Chem 1992; 38: 263–270.
Wilcox AJ, Baird DD, Dunson D, McCheaney R, Weinberg CR. Natural limits of pregnancy testing in relation to the expected menstrual period. J Am Med Assoc 2001; 286: 1759–1761.
Aswood ER. Evaluating health and maturation of the unborn: the role of the clinical laboratory. Clin Chem 1992; 38: 1523–1529.
Aswood ER. Clinical chemistry of pregnancy. In; Burtis CA, Aswood EK, eds. Tier Textbook of Clinical Chemistry, 3rd ed. Philadelphia, Saunders, 1998; 1736–1775.
Kovaleskaya G, Genbacev O, Fisher SJ, Caceres E, O’ Connor JF. Trophoblast origin of hCG isoforms: cytotrophoblasts are the primary source of choriocarcinoma-like hCG. Mol Cell Endocrinol 2002; 94: 147–155.
Cole, LA, Immunoassay of hCG, its free subunits and metabolites. Clin Chem 1997; 43: 2233–2243.
O’Connor JF, Ellish N, Kakuma T, Schlatterer J, Kovalevskaya G. Differential urinary gonadotrophin profiles in early pregnancy and early pregnancy loss. Prenatal Diagnosis 1998; 18: 1232–1240.
Stoning PL, Gaines-Das RE, Bangham DR. International reference preparation of human chorionic gonadotrophin for immunoassay: potency estimates in various bioassay and protein binding assay systems; and international reference preparations of the a and 13 subunits of human chorionic gonadotrophin for immunoassay. J Endocr 1980; 84; 295–310.
Cole LA, Cermik D, Bahado-Singh R. Oligosaccharide variants of hCG-related molecules: potential screening markers for Down syndrome. Prenat Diagn 1997; 17: 1188–1190.
Birken S, Berger P, Bidart J-M, et al. Preparation and characterization of new W.H.O. reference reagents for human chorionic gonadotropin (hCG) and metabolites. Clin Chem 2002; 49: 144–154.
Sutton JM, Higgins TN, Cembrowski GS, Cole LA. Source of inter-assay variations in hCG test results. Clin Chem submitted 2003 (to be updated at proof).
College of American Pathologists, Ligand Assay Series, CA-B 2002 Survey, 2002; p. 32.
Bock JL. hCG assays: a plea for uniformity. Am J Clin Path 1990;93:432–433.
Canfield RE, Ross GT. A new reference preparation of human chorionic gonadotrophin and its subunits. Bull World Health Organization 1976; 54: 463–72.
Khanlian S, Davies S, Sutton JM, Cole LA, Rayburn WF. Utility of home pregnancy test kits at the time of missed menses. Am J Obstet Gynecol, submitted, 2004. In press.
Cole LA. Phantom hCG and phantom choriocarcinoma. Gynecol Oncol 1998; 71: 325–329.
Wilcox AJ, Weinberg CR, O’Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med 1988; 319: 189–194.
Bjercke S, Tanbo T, Dale PO, Morkrid L, Abyholm T. Human chorionic gonadotrophin concentrations in early pregnancy after in-vitro fertilization. Human Reprod 1999; 14: 1642–1646.
Yoo A, Zaccaro J. Falsely low hCG level in a patient with hydatidiform mole caused by the “high-dose hook effect. ” Lab Med 2000; 31: 431–435.
Witherspoon LR, Schuler SE, Joseph GF, Baird GF, Neely HR, Sonnemaker RE. Immunoassay for quantifying choriogonadotropin compared for assay performance and clinical application. Clin Chem 1992; 38: 887–894.
Forest JC, Masse J, Lane A. Evaluation of the analytical performance of the Boehringer Mannheim Elecsys 2010 immunoanalyzer. Clin Biochem 1998; 31: 81–88.
Levavi H, Neri A, Bar J, Regev D, Nordenberg J, Ovadia J. “Hook effect” in complete hydatidiform molar pregnancy: a falsely low level of beta-hCG. Obstet Gynecol 1993; 82: 720–721.
Stickle DF, Gronowski AM, Olsen GA, Fellows PA, Avery MB, Studts DJ. Decreased signal intensity of Sure-Vue serum/urine qualitative hCG test at very high [hCG]. Clin Chem 2000; 46: A3.
Hussa RO, Rinke ML, Schweitzer PG. Discordant human chorionic gonadotropin results: causes and solutions. Obstet Gynecol 1985; 65: 211–219.
Vladutiu AO, Sulewski JM, Pudlak KA, Stull CG. Heterophilic antibodies interfering with radioimmunoassay: a false-positive pregnancy test. J Am Med Assoc 1982; 248: 2489–2490.
Ward G, McKinnon L, Badrick T, Hickman PE. Heterophillic antibodies remain a problem for the immunoassay laboratory. Am J Clin Path 1997; 108: 417–421.
Rotmensch S, Cole LA. False diagnosis and needless therapy of presumed malignant disease in women with false-positive human chorionic gonadotropin concentrations. Lancet 2000; 355: 712–715.
Cole LA, Butler SA. False positive or phantom hCG result: a serious problem. Clin Lab Intl 2001; 25: 9–14.
Cole LA, Rinne KM, Shababi S, Omrani A. False positive hCG assay results leading to unnecessary surgery and chemotherapy and needless occurrence of diabetes and coma. Clin Chem 1999; 45: 313–314.
Butler SA, Cole LA. The use of heterophilic antibody blocking agent (HBT) in reducing false positive hCG results. Clin Chem 2001; 47: 1332–1333.
Cole LA, Butler SA. hCG, its free subunits and metabolites in trophoblastic diseases. J Reprod Med 2002; 47: 433–444.
Olsen TG, Hubert PR, Nycum LR. Falsely elevated human chorionic gonadotrophin leading to unnecessary therapy. Obstet Gynecol 2001; 98: 843–845.
Covinsky M, Laterza O, Pfeifer JD, Farkas-Szallasi T, Scott MG. An IgM antibody to E. coli produces false positive results in multiple immunometric assays. Clin Chem 2000; 46: 1157–1161.
Birken S, Armstrong EG, Kolks MAG, et al. Structure of human chorionic gonadotropin 3-subunit core fragment from pregnancy urine. Endocrinology 1988; 123; 572–580.
Morgan FJ, Birken S, Canfield RE. The amino acid sequence of human chorionic gonadotropin: the a subunit and [1-subunit. J Biol Chem 1975; 2250; 5247–5257.
Lapthorn AJ, Harris DC, Littlejohn A, et al. Crystal structure of human chorionic gonadotropin. Nature 1994; 369; 455–460.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press, Totowa, NJ
About this chapter
Cite this chapter
Cole, L.A. (2004). Human Chorionic Gonadotropin. In: Gronowski, A.M. (eds) Handbook of Clinical Laboratory Testing During Pregnancy. Current Clinical Pathology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-787-1_2
Download citation
DOI: https://doi.org/10.1007/978-1-59259-787-1_2
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9862-2
Online ISBN: 978-1-59259-787-1
eBook Packages: Springer Book Archive